Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…Abstract Number: 128 • 2020 Pediatric Rheumatology Symposium
Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE), but there are limited studies identifying predictors of…Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…Abstract Number: 418 • 2019 ACR/ARP Annual Meeting
Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study
Background/Purpose: Axial spondyloarthritis (axSpA) usually affects young people and may lead to work disability(WD). We used the "Smart-phone SpondyloArthritis Management System”, an interactive mobile health…Abstract Number: 1475 • 2019 ACR/ARP Annual Meeting
Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies
Background/Purpose: An international task force has agreed that remission or low disease activity (LDA) are key treatment targets for patients (pts) with PsA, and recommends…Abstract Number: 2767 • 2019 ACR/ARP Annual Meeting
Importance of Discussing RA Treatment Goals: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed
Background/Purpose: Treat-to-target is a guiding principle in the management of rheumatoid arthritis (RA), and randomized clinical trials demonstrate its value in improving outcomes. However, implementation…Abstract Number: 453 • 2019 ACR/ARP Annual Meeting
Including Pain, Fatigue and Functionality Regularly in the Assessment of Patients with Early Rheumatoid Arthritis Separately Adds to the Evaluation of Disease Status
Background/Purpose: Rheumatoid arthritis (RA) level of disease activity, cannot be evaluated by a single clinical or laboratory measurement. Hence, composite indices have been created via…Abstract Number: 1516 • 2019 ACR/ARP Annual Meeting
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) is an outcome measure of disease activity entirely derived from patient self-reported measures (Health Assessment…Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…Abstract Number: 468 • 2019 ACR/ARP Annual Meeting
Effect of Body Mass Index on the Disease Activity of Patients with Rheumatoid Arthritis in a Gender Specific Manner and Association of Respective Serum C – Reactive Protein Levels with the Body’s Inflammatory Status
Background/Purpose: Current literature evaluating the effect of high Body Mass Index (BMI) on the disease activity of patients with rheumatoid arthritis (RA) is mixed as…Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…Abstract Number: 2796 • 2019 ACR/ARP Annual Meeting
The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort
Background/Purpose: Omega-3 supplementation is one of a few complementary and alternative medicine (CAM) therapies that has shown promise in improving RA symptoms through small, randomized…
- 1
- 2
- 3
- …
- 54
- Next Page »